SpyGlass Pharma, Inc. Common Stock
NASDAQ:SGPBiotechnology
+$0.45 today
- Market cap
- $993.14M
- Beta
- -0.34
- P/E (TTM)
- -14.1
- EPS (TTM)
- -$1.32
Volume 0.10M
Average 0.09M
SGP Sales of Investments
Cash received from selling or redeeming investments.
SpyGlass Pharma, Inc. Common StockNASDAQ: SGP
Sales of Investments · Q1 FY2026 · quarter ended Mar 2026
Sales of investments of $3.01M in Q1 FY2026
Q1 FY2026 sales of investments was $3.01M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Sales of Investments history
USD · from the cash flow
- Latest · FY2025
- 6M USD
- Year-over-year change
- —
| Period | Period end | Sales of Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6M | — |
Sales of Investments vs competitors
How SGP compares with its peers on the latest reported figures
- Peers report in different currencies, so sales of investments is compared through growth and share of revenue rather than absolute size.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $314.34M USD | +33.1% | +37.0% | 4127.9% | |
| LTM Mar 2026 | $310M USD | +35.4% | +0.6% | 243.2% | |
| LTM Jun 2026 | $185.16M USD | -22.8% | +13.4% | 30.2% | |
| LTM Apr 2026 | $83.12M USD | +11.5% | +93.8% | 28.6% | |
| LTM Jun 2026 | $7.92M USD | -32.6% | -28.6% | 0.1% | |
| LTM Sep 2026 | $7M USD | -95.3% | +24.9% | 0.1% | |
SGPSpyGlass Pharma, Inc. Common Stock | FY2025 | $6M USD | — | — | — |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | CHF 0 CHF | — | — | 0.0% | |
| Peer median (excluding SGP) | — | -5.6% | +19.2% | 0.1% | |
Competitors are the stored peer set for SGP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2025 Dec 2025 |
|---|---|
| Net Income | (39.87M) |
| Depreciation & Amortization | 612K |
| Deferred Income Tax | 0 |
| Stock-Based Compensation | 2.79M |
| Change in Working Capital | 2.45M |
| Accounts Receivables | (8K) |
| Inventory | 0 |
| Accounts Payables | 549K |
| Other Working Capital | 1.91M |
| Other Non-Cash Items | 1.32M |
| Operating Cash Flow | (32.7M) |
| Capital Expenditures | (789K) |
| Acquisitions (Net) | 0 |
| Purchases of Investments | (17M) |
| Sales of Investments | 6M |
| Other Investing Activities | 0 |
| Investing Cash Flow | (11.79M) |
| Debt Repayment | 0 |
| Common Stock Issued | 170K |
| Common Stock Repurchased | (1.45M) |
| Dividends Paid | 0 |
| Other Financing Activities | (1.47M) |
| Financing Cash Flow | 124.59M |
| Effect of Forex Changes | 0 |
| Net Change in Cash | 80.09M |
| Free Cash Flow | (33.49M) |
SpyGlass Pharma, Inc. Common Stock
NASDAQ:SGP
Intrinsic Alpha fair value
Locked
Current Price
$29.68
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.